Jane Henderson Sells 6,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) CFO Jane Henderson sold 6,000 shares of the firm's stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $48.26, for a total transaction of $289,560.00. Following the completion of the sale, the chief financial officer now directly owns 200,871 shares of the company's stock, valued at approximately $9,694,034.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Apogee Therapeutics Stock Performance

NASDAQ APGE traded up $0.54 on Friday, reaching $48.36. 384,313 shares of the stock traded hands, compared to its average volume of 526,857. Apogee Therapeutics, Inc. has a 12 month low of $14.19 and a 12 month high of $72.29. The company has a fifty day moving average price of $43.57 and a 200-day moving average price of $48.02. The company has a market cap of $2.83 billion and a price-to-earnings ratio of -9.21.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.60). As a group, research analysts anticipate that Apogee Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apogee Therapeutics

Several hedge funds have recently modified their holdings of the business. Darwin Global Management Ltd. bought a new position in Apogee Therapeutics in the first quarter worth approximately $55,300,000. Vanguard Group Inc. boosted its position in Apogee Therapeutics by 60.7% during the 1st quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company's stock valued at $124,173,000 after acquiring an additional 705,795 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Apogee Therapeutics by 51.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,170,327 shares of the company's stock valued at $77,770,000 after acquiring an additional 399,646 shares during the period. Farallon Capital Management LLC bought a new position in shares of Apogee Therapeutics in the 1st quarter worth $20,267,000. Finally, Affinity Asset Advisors LLC lifted its stake in shares of Apogee Therapeutics by 41.2% during the 2nd quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company's stock worth $32,908,000 after purchasing an additional 244,190 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wedbush reiterated an "outperform" rating and issued a $87.00 price target on shares of Apogee Therapeutics in a report on Monday, May 13th. Bank of America started coverage on Apogee Therapeutics in a research report on Friday, May 10th. They set a "buy" rating and a $80.00 target price for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics has a consensus rating of "Buy" and an average target price of $73.00.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.